RSLS logo

ReShape Lifesciences (RSLS) Cash From Operations

Annual CFO

-$16.96 M
+$4.94 M+22.56%

December 31, 2023

Summary

Performance

1-Year Change

+22.56%

3-Year Change

-98.36%

5-Year Change

+38.3%

15-Year Change

+31.02%

RSLS Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

50.45%
RSLS annual cash flow from operations is higher than 50.45% of companies in Healthcare sector

High & Low

All-time High

-$8.55 M

3-Year Low

-$21.90 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
RSLS previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Apr 1, 2025
RSLS next annual earnings announcement is scheduled for Apr 1, 2025

OtherRSLScash flowmetrics:

Annual CFI

-$10.00 K
RSLS annual cash flow from investing activities is -$10.00 thousand

Annual CFF

$17.57 M
RSLS annual cash flow from financing activities is $17.57 million

Annual FCF

-$17.00 M
RSLS annual free cash flow is -$17.00 million

Annual CAPEX

$43.00 K
RSLS annual capital expenditures is $43.00 thousand

Quarterly CFO

-$311.00 K
+$1.05 M+77.08%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

0%

5-Year Change

0%

RSLS Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

72.89%
RSLS quarterly cash flow from operations is higher than 72.89% of companies in Healthcare sector

High & Low

All-time High

-$311.00 K
RSLS quarterly cash flow from operations is currently at an all-time high

3-Year Low

-$7.38 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
RSLS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 1, 2025
RSLS next earnings announcement is scheduled for Apr 1, 2025

OtherRSLScash flowmetrics:

Quarterly CFI

$0.00
RSLS quarterly cash flow from investing activities is $0.00

Quarterly CFF

$0.00
RSLS quarterly cash flow from financing activities is $0.00

Quarterly FCF

-$311.00 K
RSLS quarterly free cash flow is -$311.00 thousand

Quarterly CAPEX

-
RSLS quarterly capital expenditures value is unknown

TTM CFO

-$6.20 M
+$2.47 M+28.49%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

0%

3-Year Change

0%

5-Year Change

0%

RSLS TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

66.2%
RSLS TTM cash flow from operations is higher than 66.2% of companies in Healthcare sector

High & Low

All-time High

-$6.20 M
RSLS TTM cash flow from operations is currently at an all-time high

3-Year Low

-$25.03 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
RSLS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 1, 2025
RSLS next earnings announcement is scheduled for Apr 1, 2025

OtherRSLScash flowmetrics:

TTM CFI

$0.00
RSLS TTM cash flow from investing activities is $0.00

TTM CFF

$5.49 M
RSLS TTM cash flow from financing activities is $5.49 million

TTM FCF

-$6.20 M
RSLS TTM free cash flow is -$6.20 million

TTM CAPEX

-
RSLS TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

RSLS Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+22.6%0.0%0.0%
3 y3 years-98.4%0.0%0.0%
5 y5 years+38.3%0.0%0.0%

RSLS Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-10.3%+22.6%at high+95.8%at high+75.2%
5 y5-year-98.4%+22.6%at high+96.0%at high+75.2%
alltimeall time-98.4%+49.6%at high+96.7%at high+81.6%

ReShape Lifesciences Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$311.00 K(-77.1%)
-$6.20 M(-28.5%)
Jun 2024
-
-$1.36 M(-34.5%)
-$8.67 M(-38.0%)
Mar 2024
-
-$2.07 M(-15.7%)
-$13.97 M(-17.6%)
Dec 2023
-$16.96 M(-22.6%)
-$2.46 M(-11.6%)
-$16.96 M(-2.1%)
Sep 2023
-
-$2.78 M(-58.3%)
-$17.33 M(-12.6%)
Jun 2023
-
-$6.66 M(+31.6%)
-$19.82 M(+1.2%)
Mar 2023
-
-$5.06 M(+78.9%)
-$19.59 M(-10.6%)
Dec 2022
-$21.90 M(+42.5%)
-$2.83 M(-46.3%)
-$21.90 M(-2.7%)
Sep 2022
-
-$5.27 M(-17.9%)
-$22.50 M(-10.1%)
Jun 2022
-
-$6.42 M(-13.0%)
-$25.03 M(+20.4%)
Mar 2022
-
-$7.38 M(+115.4%)
-$20.79 M(+35.2%)
Dec 2021
-$15.38 M(+79.8%)
-$3.43 M(-56.1%)
-$15.38 M(+12.1%)
Sep 2021
-
-$7.80 M(+256.5%)
-$13.71 M(+99.1%)
Jun 2021
-
-$2.19 M(+11.6%)
-$6.89 M(-5.2%)
Mar 2021
-
-$1.96 M(+11.3%)
-$7.27 M(-15.0%)
Dec 2020
-$8.55 M(-39.8%)
-$1.76 M(+80.5%)
-$8.55 M(+5.4%)
Sep 2020
-
-$976.00 K(-62.0%)
-$8.11 M(-28.9%)
Jun 2020
-
-$2.57 M(-20.9%)
-$11.41 M(-2.8%)
Mar 2020
-
-$3.25 M(+145.6%)
-$11.75 M(-17.3%)
Dec 2019
-$14.20 M(-48.3%)
-$1.32 M(-69.1%)
-$14.20 M(-28.9%)
Sep 2019
-
-$4.28 M(+47.6%)
-$19.97 M(-1.5%)
Jun 2019
-
-$2.90 M(-49.1%)
-$20.27 M(-15.1%)
Mar 2019
-
-$5.70 M(-19.6%)
-$23.87 M(-13.2%)
Dec 2018
-$27.49 M(+11.8%)
-$7.09 M(+54.9%)
-$27.49 M(-6.0%)
Sep 2018
-
-$4.58 M(-29.6%)
-$29.26 M(-3.5%)
Jun 2018
-
-$6.50 M(-30.2%)
-$30.33 M(+2.9%)
Mar 2018
-
-$9.32 M(+5.2%)
-$29.47 M(+19.8%)
Dec 2017
-$24.59 M(+19.0%)
-$8.86 M(+57.0%)
-$24.59 M(+27.7%)
Sep 2017
-
-$5.64 M(-0.1%)
-$19.26 M(+5.5%)
Jun 2017
-
-$5.65 M(+27.1%)
-$18.25 M(+0.3%)
Mar 2017
-
-$4.44 M(+25.7%)
-$18.20 M(-11.9%)
Dec 2016
-$20.66 M(-8.6%)
-$3.53 M(-23.7%)
-$20.66 M(-8.1%)
Sep 2016
-
-$4.63 M(-17.1%)
-$22.49 M(-5.9%)
Jun 2016
-
-$5.59 M(-19.0%)
-$23.89 M(+0.0%)
Mar 2016
-
-$6.90 M(+28.6%)
-$23.88 M(+5.7%)
DateAnnualQuarterlyTTM
Dec 2015
-$22.61 M(+16.6%)
-$5.36 M(-11.1%)
-$22.61 M(+4.3%)
Sep 2015
-
-$6.03 M(+8.0%)
-$21.67 M(+8.3%)
Jun 2015
-
-$5.59 M(-0.6%)
-$20.02 M(+3.2%)
Mar 2015
-
-$5.62 M(+26.9%)
-$19.40 M(+0.1%)
Dec 2014
-$19.38 M(+5.2%)
-$4.43 M(+1.1%)
-$19.38 M(+0.6%)
Sep 2014
-
-$4.38 M(-11.9%)
-$19.27 M(+2.6%)
Jun 2014
-
-$4.97 M(-11.2%)
-$18.78 M(-1.5%)
Mar 2014
-
-$5.60 M(+29.9%)
-$19.05 M(+3.4%)
Dec 2013
-$18.43 M(-18.0%)
-$4.31 M(+10.9%)
-$18.43 M(-6.0%)
Sep 2013
-
-$3.89 M(-26.0%)
-$19.60 M(-2.9%)
Jun 2013
-
-$5.25 M(+5.6%)
-$20.18 M(+0.5%)
Mar 2013
-
-$4.97 M(-9.3%)
-$20.08 M(-10.7%)
Dec 2012
-$22.48 M(+12.8%)
-$5.49 M(+22.6%)
-$22.48 M(+0.3%)
Sep 2012
-
-$4.47 M(-13.1%)
-$22.41 M(-3.1%)
Jun 2012
-
-$5.15 M(-30.2%)
-$23.12 M(+2.7%)
Mar 2012
-
-$7.37 M(+36.2%)
-$22.51 M(+12.9%)
Dec 2011
-$19.94 M(+45.9%)
-$5.41 M(+4.3%)
-$19.94 M(+10.4%)
Sep 2011
-
-$5.19 M(+14.5%)
-$18.06 M(+13.9%)
Jun 2011
-
-$4.53 M(-5.5%)
-$15.85 M(+6.9%)
Mar 2011
-
-$4.80 M(+35.7%)
-$14.83 M(+8.5%)
Dec 2010
-$13.66 M(-44.6%)
-$3.54 M(+18.6%)
-$13.66 M(-21.3%)
Sep 2010
-
-$2.98 M(-15.1%)
-$17.37 M(-14.7%)
Jun 2010
-
-$3.51 M(-3.4%)
-$20.35 M(-8.1%)
Mar 2010
-
-$3.63 M(-49.8%)
-$22.14 M(-10.2%)
Dec 2009
-$24.66 M(-26.8%)
-$7.24 M(+21.4%)
-$24.66 M(-8.4%)
Sep 2009
-
-$5.97 M(+12.7%)
-$26.93 M(-8.4%)
Jun 2009
-
-$5.30 M(-14.0%)
-$29.38 M(-8.6%)
Mar 2009
-
-$6.16 M(-35.3%)
-$32.15 M(-4.5%)
Dec 2008
-$33.67 M(+44.1%)
-$9.51 M(+12.9%)
-$33.67 M(+39.4%)
Sep 2008
-
-$8.42 M(+4.5%)
-$24.16 M(+53.5%)
Jun 2008
-
-$8.06 M(+5.0%)
-$15.74 M(+105.0%)
Mar 2008
-
-$7.68 M
-$7.68 M
Dec 2007
-$23.37 M(+44.0%)
-
-
Dec 2006
-$16.23 M(+57.9%)
-
-
Dec 2005
-$10.28 M
-
-

FAQ

  • What is ReShape Lifesciences annual cash flow from operations?
  • What is the all time high annual CFO for ReShape Lifesciences?
  • What is ReShape Lifesciences annual CFO year-on-year change?
  • What is ReShape Lifesciences quarterly cash flow from operations?
  • What is the all time high quarterly CFO for ReShape Lifesciences?
  • What is ReShape Lifesciences quarterly CFO year-on-year change?
  • What is ReShape Lifesciences TTM cash flow from operations?
  • What is the all time high TTM CFO for ReShape Lifesciences?
  • What is ReShape Lifesciences TTM CFO year-on-year change?

What is ReShape Lifesciences annual cash flow from operations?

The current annual CFO of RSLS is -$16.96 M

What is the all time high annual CFO for ReShape Lifesciences?

ReShape Lifesciences all-time high annual cash flow from operations is -$8.55 M

What is ReShape Lifesciences annual CFO year-on-year change?

Over the past year, RSLS annual cash flow from operations has changed by +$4.94 M (+22.56%)

What is ReShape Lifesciences quarterly cash flow from operations?

The current quarterly CFO of RSLS is -$311.00 K

What is the all time high quarterly CFO for ReShape Lifesciences?

ReShape Lifesciences all-time high quarterly cash flow from operations is -$311.00 K

What is ReShape Lifesciences quarterly CFO year-on-year change?

Over the past year, RSLS quarterly cash flow from operations has changed by $0.00 (0.00%)

What is ReShape Lifesciences TTM cash flow from operations?

The current TTM CFO of RSLS is -$6.20 M

What is the all time high TTM CFO for ReShape Lifesciences?

ReShape Lifesciences all-time high TTM cash flow from operations is -$6.20 M

What is ReShape Lifesciences TTM CFO year-on-year change?

Over the past year, RSLS TTM cash flow from operations has changed by $0.00 (0.00%)